Clinical diagnostics

Bring precision diagnostics to the frontline

Precision medicine involves a transition from the cellular analysis of traditional diagnostics to transcriptomics and genetic analysis. The larger and more complex datasets can lead to important improvements in disease identification, classification and ultimately treatment strategies. 

Until recently, the faster, larger and more complex dataset generation from NGS has not been matched by equally efficient analysis tools and clinical solutions. With its power, simplicity and instantly visualized response to input, Qlucore makes it possible for clinical labs to explore disease sub-classification and validate results more efficiently onsite and without the need for specialized training. We are also working to develop IVDR-certified disease-specific diagnostic tools. 


Cancer diagnostics: in transformation

cancer diagnostics

Cancer diagnostics is an area in transformation which is quickly moving towards precision-based treatments for several cancer types. One driver for this is the lowered cost for genetics measurements. Here we are playing an important role and our prototype for RNA-seq based cancer diagnostics is already being tested by clinical labs. 

Unique functionality for easy deployment

Qlucore solutions include machine learning based subtype classification and gene fusion analysis, combined with easy-to-understand reporting and visualization for clear communication.

  • AI-powered, disease-specific machine learning classifier models based on gene expression. 
  • Plug-in software architecture for scalability to multiple disease areas. 
  • Tier-based gene fusion reporting. 
  • Patient-friendly visualizations in an easy-to-use and cost-effective software solution.  
  • Based on RNA sequencing data and standard NGS workflows. 

Falling costs

Driven by the falling costs of Next Generation Sequencing (NGS) techniques, precision diagnostics and personalized treatments are improving at a fast pace.

RNA-seq based cancer diagnostics

International research efforts have demonstrated that transcriptional profiling of cancer has a great clinical utility to significantly improve clinical diagnostics, prognostication and therapy selection. Detection and analysis of gene fusions and expression-based classification is moving quickly from research to clinical use.  Gene fusions provide important examples of genetic alterations that can be detected by RNA-sequencing and that are important diagnostic markers according to the current guidelines of leukemia (ALL and AML).

Transcriptomics - paving the way for improved diagnostics and precision medicine 

The rapid development of NGS techniques is moving the clinical diagnostics field from using small gene panels to more comprehensive techniques. The number of drug candidates targeting gene fusions is increasing, and with them comes the need for larger screening for better diagnosis and treatment selection. 

Whole transcriptome RNA-seq data provides unbiased gene fusion detection and a gene expression signature of the tumor - important components for patient subtype classification and correct diagnosis. 

The latest developments in precision medicine require clinical labs to stay up to date and to implement new techniques. 

With Qlucore’s clinical diagnostics solutions the transition is easier, and you can start your transition today. 

By using Qlucore solutions you can begin this transition in your lab. There are currently more than 300 genes that are frequently involved in gene fusions in various cancers. 

Whitepaper for childhood leukemia subtype classification

Genetic classification of acute lymphoblastic leukemia (ALL)